197 General discussion 41. Sollie A, Sijmons RH, Helsper C, Numans ME. Reusability of coded data in the primary care electronic medical record: A dynamic cohort study concerning cancer diagnoses. International journal of medical informatics. 2017;99:45-52. 42. Douma LN, Uiters E, Timmermans DR. The Dutch public are positive about the colorectal cancer-screening programme, but is this a well-informed opinion? BMC public health. 2016;16(1):1-12. 43. Douma LN, Uiters E, Timmermans DR. Why are the public so positive about colorectal cancer screening? BMC Public Health. 2018;18(1):1-9. 44. Giard RW. Kritische blik op kankerscreening. Ned tijdschr geneeskd. 2022;166:D6926. 45. Voss T, Krag M, Martiny F, Heleno B, et al. 102 Quantification of overdiagnosis in randomised trials of cancer screening: an overview and re-analysis of systematic reviews. Royal Society of Medicine; 2023. 46. Vermeer B, Van den Muijsenbergh ME. The attendance of migrant women at the national breast cancer screening in the Netherlands 1997–2008. European Journal of Cancer Prevention. 2010;19(3):195-8. 47. van Leeuwen AW, de Nooijer P, Hop WC. Screening for cervical carcinoma: participation and results for ethnic groups and socioeconomic status. Cancer Cytopathology. 2005;105(5):270-6. 48. Aarts M, Voogd A, Duijm LE, Coebergh J, et al. Socioeconomic inequalities in attending the mass screening for breast cancer in the south of the Netherlands—associations with stage at diagnosis and survival. Breast cancer research and treatment. 2011;128(2):517-25. 49. De Nooijer D, De Waart F, Van Leeuwen A, Spijker W. Participation in the Dutch national screening programme for uterine cervic cancer higher after invitation by a general practitioner, especially in groups with a traditional low level of attendance. Nederlands tijdschrift voor geneeskunde. 2005;149(42):2339-43. 50. Mühlberger N, Sroczynski G, Gogollari A, Jahn B, et al. Cost effectiveness of breast cancer screening and prevention: a systematic review with a focus on risk-adapted strategies. The European Journal of Health Economics. 2021;22(8):1311-44. 51. Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer screening. Epidemiologic reviews. 2011;33(1):88-100. 52. Schrager S, Phillips G, Burnside E. Shared decision making in cancer screening. Family practice management. 2017;24(3):5. 53. Hobma S. Wat is uw advies over deelname aan het bevolkingsonderzoek borstkanker? Huisarts en wetenschap. 2019;62(10):38-. 54. der HTA-Bericht W. Warum die jährliche Krebsvorsorge beim Frauenarzt nicht zu ersetzen ist. 55. van den Brekel-Dijkstra K, Cornelissen M, van der Jagt L. De dokter gevloerd: Hoe voorkomen we burn-out bij huisartsen? Huisarts en wetenschap. 2020;63:40-3. 56. Raams E, Wiersma T. Berichtgeving door de huisarts bij bevolkingsonderzoeken. Huisarts en wetenschap. 2015;58(10):514-7. 57. Assendelft P. Huisarts en beweegadvies-waar wachten we op? Huisarts en wetenschap. 2022;65(12):28-31. 58. Scheenhart N, Azdahic A, Metting E. Preventie: een taak van de huisarts? Huisarts en wetenschap. 2021;64:19-24. 59. Landelijke Huisartsen Vereniging. Federatienieuws: Aanbod huisartsenzorg opnieuw afgebakend. Medisch Contact, 2022. 60. Kleijne I. Huisarts zet stempel met paarse krokodil in. Medisch Contact. 2019. 61. Flinterman L, Vis E, Keuper J, van Schaaijk A, et al. De arbeidsmarkt van de Nederlandse huisartsenzorg in. 2023. 7
RkJQdWJsaXNoZXIy MTk4NDMw